06:13:56 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:ICPT from 2023-04-27 to 2024-04-26 - 18 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-02-29 08:30U:ICPTNews ReleaseIntercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva(TM) (obeticholic acid) for the Treatment of PBC
2023-11-13 08:00U:ICPTNews ReleaseIntercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting ‚ ® 2023
2023-11-10 08:00U:ICPTNews ReleaseIntercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting ‚ ® 2023
2023-11-08 09:14U:ICPTNews ReleaseAlfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
2023-09-26 08:00U:ICPTNews ReleaseAlfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
2023-09-05 08:30U:ICPTNews ReleaseIntercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
2023-08-02 07:00U:ICPTNews ReleaseIntercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
2023-07-26 08:00U:ICPTNews ReleaseIntercept to Announce Second Quarter 2023 Financial Results on August 2, 2023
2023-06-23 06:30U:ICPTNews ReleaseIntercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
2023-06-23 02:45U:ICPTNews ReleaseIntercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
2023-06-22 17:45U:ICPTNews ReleaseIntercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
2023-06-07 07:00U:ICPTNews ReleaseIntercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023
2023-05-31 08:00U:ICPTNews ReleaseIntercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023
2023-05-19 18:45U:ICPTNews ReleaseIntercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
2023-05-19 07:05U:ICPTNews ReleaseIntercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
2023-05-16 17:00U:ICPTNews ReleaseIntercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
2023-04-27 07:00U:ICPTNews ReleaseIntercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
2023-04-27 06:55U:ICPTNews ReleaseIntercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program